Cost-Utility of Acromegaly Pharmacological Treatments in a French Context
ObjectiveEfficacy of pharmacological treatments for acromegaly has been assessed in many clinical or real-world studies but no study was interested in economics evaluation of these treatments in France. Therefore, the objective of this study was to estimate the cost-utility of second-line pharmacolo...
Main Authors: | Thierry Brue, Philippe Chanson, Patrice Rodien, Brigitte Delemer, Delphine Drui, Lucile Marié, Laurène Juban, Lara Salvi, Robin Henocque, Gérald Raverot |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.745843/full |
Similar Items
-
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
by: Mônica R Gadelha, et al.
Published: (2020-12-01) -
Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
by: Mônica Gadelha, et al.
Published: (2020-02-01) -
Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01) -
Pasireotide: a novel treatment for patients with acromegaly
by: Cuevas-Ramos D, et al.
Published: (2016-01-01) -
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
by: Sang Ouk Chin, et al.
Published: (2019-03-01)